CSTL
Castle Biosciences Inc

1,009
Mkt Cap
$1.14B
Volume
408,954.00
52W High
$44.28
52W Low
$14.59
PE Ratio
-86.51
CSTL Fundamentals
Price
$38.94
Prev Close
$39.47
Open
$39.47
50D MA
$39.62
Beta
1.05
Avg. Volume
382,021.80
EPS (Annual)
$0.6236
P/B
2.43
Rev/Employee
$436,358.74
Loading...
Loading...
News
all
press releases
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
Zacks·20h ago
News Placeholder
More News
News Placeholder
MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View
Merck tops Q4 EPS and sales estimates as Keytruda drives growth, but shares fall in pre-market trading as 2026 guidance disappoints.
Zacks·21h ago
News Placeholder
CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?
CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.
Zacks·24h ago
News Placeholder
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.
Zacks·1d ago
News Placeholder
Castle Biosciences, Inc. (NASDAQ:CSTL) Receives Average Recommendation of "Moderate Buy" from Analysts
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are covering the firm, Marketbeat.com reports. One equities...
MarketBeat·3d ago
News Placeholder
Viking Therapeutics to Report Q4 Earnings: Here's What to Know
VKTX heads into Q4 earnings with investor focus on VK2735's late-stage obesity studies that are witnessing rapid enrollment momentum.
Zacks·5d ago
News Placeholder
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold
Intellia jumps over 6% after the FDA lifts the clinical hold on the MAGNITUDE-2 study, clearing a path to resume dosing of nex-z in ATTRv-PN.
Zacks·7d ago
News Placeholder
SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
Zacks·8d ago
News Placeholder
The Analyst Verdict: Castle Biosciences In The Eyes Of 7 Experts
read more...
Benzinga·9d ago
News Placeholder
Are You Looking for a Top Momentum Pick? Why Castle Biosciences, Inc. (CSTL) is a Great Choice
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·12d ago
<
1
2
...
>

Latest CSTL News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.